HOME >> BIOLOGY >> NEWS
Results of pivotal study for GlaxoSmithKline's Valtrex published in New England Journal of Medicine

Research Triangle Park, N.C., January 1, 2004 GlaxoSmithKline today announced the publication of results from a clinical trial evaluating VALTREX (valacyclovir HCl), an oral antiviral, in the reduction of transmission of genital herpes, in the Jan. 1 edition of the New England Journal of Medicine1. VALTREX significantly reduced the risk of transmitting herpes infection to a heterosexual partner as compared to placebo. Results from this trial have been used to support a new label indication for VALTREX in the reduction in risk of transmission of genital herpes when used in combination with safer sex practices. This new indication has been approved in the USA, Australia and Finland.

The transmission study with VALTREX published in the latest edition of NEJM was a randomized, double-blind, placebo-controlled trial involving 1,484 healthy, heterosexual, monogamous couples in 21 countries. The primary endpoint of the study was to evaluate the reduction in risk of transmission of symptomatic genital herpes (signs or symptoms of GH confirmed with a lab test) to an uninfected partner with use of suppressive therapy with VALTREX. The study showed that once-daily suppressive therapy with VALTREX 500 mg caplets reduced the risk of transmission of symptomatic genital herpes by 75 percent versus placebo (0.5 percent vs 2.2 percent). In addition, suppressive therapy with VALTREX reduced the risk of overall acquisition of the virus (with or without symptoms confirmed by a lab test) by 48 percent versus placebo (1.9 percent vs. 3.6 percent). In addition, VALTREX significantly reduced the number of recurrences in the infected partner versus placebo, consistent with previous studies.

Throughout the eight-month study, all couples were counselled on safer sex practices at all study visits. The principles of safer sex practices were (1) to avoid sexual contact when the infected partner had any symptoms of genital herpes and (2) consistent and correct use of condo
'"/>

Contact: Mary Faye Dark, GlaxoSmithKline
919-483-2839
Hill and Knowlton
1-Jan-2004


Page: 1 2 3

Related biology news :

1. Results from open-label Raptiva study suggest continued benefit with long-term treatment
2. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
3. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
4. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
5. Quicker Implementation Of Research Results
6. Results Of Poisoning Visible In Urine
7. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
8. New Gene Therapy Technique Results In Efficient Gene Delivery
9. False Security: You Cant Always Believe The Results Of A Genetic Test
10. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
11. Results Of Hog-Stress Study May Lead To Better Management Methods

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
Breaking Biology Technology:
Cached News: